H-pyrrolo[2,3-c]pyridine compounds acting as menin (MEN1)/MLL interaction inhibitors and thus reported to be useful for the treatment of cancer.

Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 21.3% during the third quarter, Holdings Channel.com reports. The ...

Fintel reports that on October 24, 2024, UBS initiated coverage of Syndax Pharmaceuticals (NasdaqGS:SNDX) with a Buy ...

In a report released yesterday, Charles Zhu from LifeSci Capital maintained a Buy rating on Kura Oncology (KURA – Research Report), with ...

Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) ...

Ziftomenib, previously known as KO-539, works by blocking the interaction of two proteins — menin and KMT2A MLL — that enable certain leukemia cells to survive and multiply. It particularly ...

which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego ...

About Ziftomenib Ziftomenib is a novel, once-daily, oral investigational drug candidate targeting the menin-KMT2A/MLL protein-protein interaction for treatment of genetically defined AML patients ...

Small hotels will be exempt from certain rules under the latest version of a controversial licensing bill. City Council member Julie Menin reached a final agreement with the hotel union and ...

The Manufacturers Life Insurance Company boosted its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 16.1% in the 2nd quarter, according to the company in its most recent 13F ...

Mann was co-ordinator of tours and group sales at MLL from 2017 to 2019. She adjusted computer records to reflect higher passenger numbers for bus tour contractor Tony’s Team Transport ...